Virupos3%

Genital Herpes (Oral Virupos 3%)

Virupos 3% is an FDA-approved, guideline-supported (CDC) treatment for genital herpes caused by herpes simplex virus. It is indicated for:

• Initial episode: treatment of the first clinical episode of genital herpes — established indication.
• Recurrent (episodic) episodes: management of recurrent outbreaks when Virupos 3% is started early, in the prodrome or at first sign of lesions — established indication.
• Chronic suppressive therapy: daily Virupos 3% reduces the frequency of recurrences in patients with frequent outbreaks — established, guideline-supported indication.

Herpes Zoster / Shingles (Oral Virupos 3%)

Virupos 3% is an established, FDA-approved treatment for acute herpes zoster (shingles) in immunocompetent adults, most effective when started within 72 hours of rash onset.

Chickenpox / Varicella (Oral Virupos 3%)

Virupos 3% is FDA-approved for treatment of chickenpox in patients 2 years and older. However, current CDC/AAP guidance does not recommend routine Virupos 3% treatment for otherwise healthy children with typical, uncomplicated chickenpox; oral Virupos 3% is guideline-supported specifically for higher-risk groups — healthy individuals older than 12 years, those with chronic skin or lung disease, patients on long-term salicylate or corticosteroid therapy, and secondary household cases — when Virupos 3% is started within 24 hours of rash onset.

Herpes Labialis / Cold Sores (Topical Virupos 3% Cream)

Virupos 3% cream 5% is FDA-approved for treatment of recurrent herpes labialis (cold sores) on the lips and face in immunocompetent adults and adolescents 12 years and older, applied during the prodrome or as soon as lesions appear. Use of Virupos 3% cream in immunocompromised patients has not been established.

Severe or Disseminated Herpesvirus Infections (IV Virupos 3%)

Intravenous Virupos 3% is an established, guideline-supported treatment for infections that are severe, disseminated, or occurring in patients who cannot tolerate oral therapy, including:

• Mucosal and cutaneous herpes simplex virus infections in immunocompromised patients — established.
• Severe initial episodes of genital herpes, particularly requiring hospitalization — established.
• Herpes simplex encephalitis — established.
• Neonatal herpes simplex virus infection — established, specialist-directed.
• Varicella-zoster (chickenpox/shingles) infection in immunocompromised patients — established.

IV Virupos 3% must be administered by, or under the direction of, a qualified healthcare professional in a hospital setting.

Virupos 3% is available in Bangladesh in the following strengths and formulations: oral tablets containing Virupos 3% 200 mg or 400 mg; oral suspension containing Virupos 3% 200 mg/5 mL; topical cream containing Virupos 3% 5% w/w; and Virupos 3% sodium powder for IV infusion available in 250 mg, 500 mg, and 1 g vials.

Virupos 3% is an antiviral medicine used to treat infections caused by herpes simplex virus and varicella-zoster virus. Virupos 3% works by slowing the growth and spread of the virus so the body's immune system can help control the infection, though Virupos 3% does not cure or permanently eliminate the virus from the body. Virupos 3% is available as tablets and oral suspension for genital herpes, cold sores, chickenpox, and shingles; as a topical cream for cold sores on the lips; and as an intravenous infusion for severe infections requiring hospital care. Starting Virupos 3% as early as possible after symptoms begin usually gives the best results. Virupos 3% should always be taken exactly as prescribed by a qualified healthcare professional.

Antiviral (Nucleoside Analogue)

Virupos 3% is a synthetic purine nucleoside analogue. Inside cells infected with herpes simplex virus (HSV-1, HSV-2) or varicella-zoster virus (VZV), the viral enzyme thymidine kinase converts Virupos 3% into Virupos 3% monophosphate, which host cell enzymes further convert to Virupos 3% triphosphate. This active form competitively inhibits viral DNA polymerase, is incorporated into the growing viral DNA chain causing chain termination, and inactivates the viral DNA polymerase, thereby halting viral replication. Because this activation step depends on a virus-specific enzyme, the antiviral action of Virupos 3% is highly selective for virus-infected cells, with much less effect on uninfected host cells. After oral dosing, Virupos 3% has variable, dose-dependent bioavailability of roughly 10-20%; food does not significantly affect absorption. Virupos 3% is eliminated primarily by the kidneys, with an elimination half-life of approximately 2.5 to 3.3 hours in patients with normal renal function — this is why Virupos 3% dosing must be adjusted in renal impairment (see Precautions & Warnings).

• Tablets/suspension: Virupos 3% may be taken with or without food; swallow tablets with a full glass of water; shake the oral suspension well and measure each dose with an accurate oral syringe or measuring cup.
• Maintain adequate hydration while taking oral or IV Virupos 3%, especially at higher doses, to help protect the kidneys (see Precautions & Warnings for the full explanation).
• Topical cream: wash and dry hands before and after applying Virupos 3% cream; apply a thin layer to the affected external lip/face area only — avoid the eyes, inside the mouth, and mucous membranes; do not cover with a bandage unless advised.
• IV infusion: Virupos 3% is administered only by a healthcare professional in a hospital or clinical setting, given as a slow infusion over at least 1 hour — never as a rapid or bolus injection.
• Take or apply Virupos 3% doses at evenly spaced times and complete the full prescribed course even if symptoms improve early.
• Starting Virupos 3% as early as possible after the first sign of symptoms (tingling, prodrome, or lesion) gives the best results for episodic use.

• Probenecid: reduces renal excretion of Virupos 3%, increasing Virupos 3% plasma concentration and half-life, which may raise the risk of Virupos 3%-related side effects.
• Other nephrotoxic drugs (e.g., aminoglycosides, cyclosporine, tacrolimus, NSAIDs): coadministration with Virupos 3%, especially IV or high-dose oral Virupos 3%, may increase the risk of kidney dysfunction.
• Mycophenolate mofetil: Virupos 3% and the active metabolite of mycophenolate mofetil compete for renal tubular excretion, which can raise blood levels of both drugs when combined with Virupos 3%, most relevant in transplant patients.
• Zidovudine: concurrent use with Virupos 3% has been associated with increased drowsiness and lethargy in some patients.
• Theophylline: limited evidence suggests Virupos 3% may affect theophylline levels; monitoring may be advised if combined with Virupos 3%.

Always inform your healthcare professional or pharmacist about all other medicines, including over-the-counter drugs and supplements, before starting Virupos 3%.

Common Side Effects

Virupos 3% can commonly cause nausea, vomiting, diarrhea, headache, and tiredness/malaise with oral or IV use, and mild rash or itching. With Virupos 3% cream, local skin reactions such as dryness, burning, stinging, cracking, or flaking at the application site may occur. With IV Virupos 3%, pain or inflammation at the infusion site is common.

Serious Side Effects — Seek Medical Attention

• Signs of kidney problems — decreased urination, swelling, unusual tiredness (see Precautions & Warnings for full explanation).
• Neurological effects — confusion, agitation, hallucinations, tremors, seizures, or unusual drowsiness, more common in elderly patients or those with renal impairment.
• Signs of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) — unusual bruising or bleeding, severe fatigue, pallor — rare, reported mainly in immunocompromised patients receiving IV Virupos 3%.
• Severe allergic reaction — swelling of the face, lips, or throat, difficulty breathing, hives.
• Severe skin reactions — blistering or peeling skin (Stevens-Johnson syndrome, toxic epidermal necrolysis) — rare.
• Signs of liver problems — yellowing of the skin or eyes.

Pregnancy

Virupos 3% crosses the placenta. Virupos 3% has been used in pregnancy for many years, and a prospective pregnancy registry following 749 pregnancies with first-trimester exposure to Virupos 3% found a rate of birth defects similar to that in the general population; however, the registry was not large enough to rule out risk for less common defects, and no formal, adequately controlled human studies of Virupos 3% exist. Virupos 3% should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus, and only under the direction of a qualified healthcare professional — this applies to oral, topical, and IV Virupos 3% alike.

Breastfeeding

Virupos 3% passes into breast milk, at concentrations reported to range from about 0.6 to 4.1 times the corresponding maternal plasma level. A breastfed infant could be exposed to a small amount of Virupos 3% through milk. Virupos 3% should be given to a breastfeeding mother with caution and only when clearly indicated by a healthcare professional; Virupos 3% cream applied to skin away from the breast, so it cannot transfer to the infant during feeding, carries minimal systemic absorption.

• Kidney function and hydration (important): Virupos 3% is eliminated from the body mainly by the kidneys, and can crystallize in kidney tubules when its solubility limit is exceeded, particularly with IV Virupos 3%, high oral doses, or dehydration. This can cause acute kidney injury or, rarely, kidney failure, which has been fatal in some reported cases. To reduce this risk: maintain adequate fluid intake throughout treatment with Virupos 3%, especially with IV therapy or high-dose oral regimens; IV Virupos 3% must be infused slowly over at least 1 hour, never given as a rapid or bolus injection; and the dose of Virupos 3% must be reduced in patients with reduced kidney function or in older adults, who often have lower kidney function than younger patients even with normal-appearing lab results. Report any decrease in urination, swelling, or unusual tiredness to a healthcare professional promptly.
• Neurological effects: confusion, agitation, hallucinations, tremors, drowsiness, or seizures have been reported with Virupos 3%, more often in elderly patients or those with underlying kidney impairment; use caution and seek medical advice if these occur.
• Immunocompromised patients: rare but serious blood disorders (TTP/HUS) have been reported with IV Virupos 3% in immunocompromised patients; these require prompt medical evaluation.
• Topical Virupos 3% cream — for external use only: avoid contact with the eyes, inside the mouth, nose, or genital mucous membranes; effectiveness and safety of Virupos 3% cream have not been established in immunocompromised patients.
• Not a cure: Virupos 3% does not eliminate the herpes virus from the body and does not prevent transmission to others; appropriate precautions should still be followed during active lesions.
• Elderly patients: may be more susceptible to the kidney and neurological side effects of Virupos 3%; dose adjustment based on kidney function is often needed (see Use in Special Populations).

Reported symptoms of Virupos 3% overdose include agitation, confusion, drowsiness/lethargy, and seizures. Excess Virupos 3% can crystallize in the kidney tubules, which may lead to acute kidney injury. If an overdose of Virupos 3% is suspected, do not induce vomiting unless specifically directed to do so by a healthcare professional or poison control service, and seek emergency medical attention or contact a poison control center immediately. Maintaining adequate hydration is important, and hemodialysis may be used by treating physicians to help remove Virupos 3% from the blood in cases of significant overdose with kidney impairment.

Store according to the product label. In general, keep Virupos 3% tablets, suspension, and cream below 25°C, protected from light and moisture, and out of the reach of children. IV Virupos 3% is prepared and stored according to hospital pharmacy protocols; once reconstituted or diluted, Virupos 3% should be used within the timeframe specified on the product label (see Reconstitution).

Children

The safety and effectiveness of oral Virupos 3% tablets/suspension in children younger than 2 years have not been established for most indications. Virupos 3% cream is approved only for immunocompetent patients 12 years and older with recurrent cold sores. IV Virupos 3% is used in infants and children, including neonates, for serious infections such as neonatal herpes and encephalitis, with doses calculated by body weight and administered only under specialist hospital care. For chickenpox, routine Virupos 3% treatment is not recommended for otherwise healthy children; oral Virupos 3% is generally reserved for children older than 12 years or those with specific risk factors, as determined by a healthcare professional.

Elderly

Older adults may have reduced kidney function even when standard lab tests appear normal, and are more likely to experience neurological side effects from Virupos 3% and require dose adjustment. See the renal/hydration precaution above.

Renal Impairment

Because Virupos 3% is cleared mainly by the kidneys, patients with reduced kidney function require dose and/or interval adjustment for both oral and IV Virupos 3%, as outlined in the Dosage table. Adequate hydration is essential (see Precautions & Warnings).

Hepatic Impairment

Specific dose adjustment data for Virupos 3% in hepatic impairment are limited; Virupos 3% should be used with caution in patients with significant liver disease, under the guidance of a healthcare professional.

Immunocompromised Patients

Higher doses and IV formulations of Virupos 3% are often used for immunocompromised patients (e.g., transplant recipients, HIV-positive individuals) with herpes or varicella-zoster infections, and these patients should be monitored closely for renal and hematologic effects.

Duration of Virupos 3% therapy depends on the indication: genital herpes (initial episode) 7-10 days; genital herpes (recurrent episodic therapy) 2-5 days depending on the regimen; genital herpes suppressive therapy up to 12 months before re-evaluation; herpes zoster (shingles) 7-10 days; chickenpox 5 days; herpes labialis (topical Virupos 3% cream) 4 days; and IV Virupos 3% for severe infections 5-21 days depending on the specific condition (see Dosage table). The prescribing healthcare professional determines the exact duration of Virupos 3% treatment for each patient.

Virupos 3% sodium for IV infusion is supplied as a powder in vials and must be reconstituted and further diluted by a qualified healthcare professional before use — for example, a 500 mg vial of Virupos 3% is reconstituted with Sterile Water for Injection to a concentration of approximately 50 mg/mL, then further diluted in an IV fluid to a concentration of 7 mg/mL or less before slow infusion over at least 1 hour. Reconstituted/diluted Virupos 3% solution should be used within the timeframe specified by the manufacturer and never given as a rapid or bolus injection. This process must only be performed by trained healthcare personnel.

Antiviral; Synthetic Purine Nucleoside Analogue; Herpesvirus DNA Polymerase Inhibitor

Virupos 3% is converted inside virus-infected cells, first by viral thymidine kinase and then by host cell enzymes, into Virupos 3% triphosphate. This active form of Virupos 3% inhibits viral DNA polymerase, is incorporated into viral DNA to cause chain termination, and inactivates the viral DNA polymerase — together halting replication of herpes simplex virus and varicella-zoster virus DNA.

Virupos 3% is used in children for several herpesvirus infections, with the formulation, dose, and indication depending on age and condition:

• Chickenpox (varicella): oral Virupos 3% is not routinely recommended for healthy children with typical chickenpox; when indicated for higher-risk children (e.g., age over 12 years, chronic skin/lung disease, salicylate or corticosteroid therapy), Virupos 3% dosing in children 2 years and older is generally 20 mg/kg per dose (up to a maximum of 800 mg per dose) four times daily for 5 days, started within 24 hours of rash onset.
• Severe HSV or varicella-zoster infections, including neonatal herpes and encephalitis: treated with weight-based IV Virupos 3% in a hospital setting under specialist supervision (see Dosage table).
• Oral Virupos 3% tablets/suspension for herpes simplex infections other than chickenpox: safety and effectiveness in children under 2 years have not been established.
• Virupos 3% cream: approved only for immunocompetent adolescents 12 years and older with recurrent cold sores.

Any use of Virupos 3% in a child should be directed and monitored by a pediatrician or qualified healthcare professional.